Results 91 to 100 of about 22,035 (254)

Virological efficacy of PI monotherapy for HIV-1 in clinical practice. [PDF]

, 2016
BACKGROUND: Clinical trials of PI monotherapy indicate that most participants maintain viral suppression and emergent protease resistance is rare.
Collier, D, Copas, AJ, El Bouzidi, K, Gupta, RK, Miller, RF, Nastouli, E   +5 more
core   +1 more source

Development and Validation of New Analytical Method for The Simultaneous Estimation of Darunavir And Ritonavir in Pharmaceutical Dosage Form

International journal of indigenous herbs and drugs, 2021
A simple, Accurate, precise method was developed for the simultaneous estimation of the Darunavir and Ritonavir in Tablet dosage form. The chromatogram was run through Agilent C18 150 x 4.6 mm, 5m.
P. Raju, K. Thejomoorthy, P. Prasanna
semanticscholar   +1 more source

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort [PDF]

, 2019
Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected ...
Abeli C., Acinapura R., alungo A., Andreoni M., Angarano G., Antinori A., aracino A., atini A., azzarin A., Bagella P., Bai F., Baldelli F., Baldin G., Balotta C., Bandera A., Barocci V., Bassetti M., Blanc P., Bobbio N., Bonfanti P., Bonora S., Borderi M., Borgia G., Cacopardo B., Calcagno A., Capetti A., Capobianchi M. R., Capozzi M., Caramello P., Carletti F., Carrara S., Cascio A., Cassola G., Castagna A., Castelli F., Castelnuovo F., Cattelan A. M., Cauda R., Ceccherini-Silberstein F., Ceccherini-Silberstein F., Cecchetto M., Celesia B., Chiodera A., Cicalini S., Cingolani A., Cinque P., Colomba C., Costantini A., Cozzi-Lepri A., Cozzi-Lepri A., Cristaudo A., d'Arminio Monforte A., De Luca A., Di Biagio A., Di Caro A., Di Giuli C., Di Martino F., Di Perri G., Esposito V., Fabrizio C., Falasca K., Fanti I., Fontana Del Vecchio R., Francisci D., Galli L., Galli M., Gentile I., Giacometti I. A., Gianotti N., Girardi E., Gori A., Graziano S., Guaraldi G., i V., Iaiani G., Iardino R., Ippolito G., Lapadula G., lessandrini A., Lichtner M., Lo Caputo S., Lorenzini P., Lorenzotti S., Macchia M., Maddaloni L., Madeddu G., Maggiolo F., Maggiolo F., Magnani G., Manfrin V., Marchetti G., Marinello S., Mastrorosa I., Mazzarello G., Menzaghi B., Migliorino C., Milini P., Minardi C., Moioli M. C., Molteni C., Mondi A., Monno L., Mussini C., Nozza S., Nunnari G., ondero A., Orofino G. C., Pan A., Parruti G., Pellicano G., Pellizzer G., Perno C. F., Petrone F., Piolini R., Plazzi M. M., Pozzetto I., Prota G., Puoti M., Puzzolante C., Quartu S., Quiros Roldan E., Rezza G., Ridolfo A. L., Rivano Capparucia M., Rizzardini G., Rodano' A., Rossetti B., Rossotti R., Rusconi S., Rusconi S., Salpietro S., Sangiovanni V., Santoro M. M., Sarmati L., Savinelli S., Schiaroli E., Sciandra M., Segala D., Sighinolfi L., Sozio F., Starnini G., Suardi C., Tavelli A., Tavelli A., Tincati C., Truffa S., Ursitti M. A., Vecchiet J., Vergori A., Verucchi G., Viale P., Vichi F., Viscoli C., Viviani F., von Schloesser F., Vullo V.   +155 more
core   +4 more sources

Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies

Human Reproduction, 2020
STUDY QUESTION Does HIV protease inhibitor (PI)-based combination antiretroviral therapy (cART) initiated at periconception affect key events in early pregnancy, i.e. decidualization and spiral artery remodeling?
Smriti Kala, C. Dunk, Sebastian Acosta, L. Serghides   +3 more
semanticscholar   +1 more source

Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS

HIV/AIDS: Research and Palliative Care, 2016
Jordi Navarro, Adrian Curran Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain Abstract: Efficacy is the main objective of antiretroviral treatment and adherence is
Navarro J, Curran A
doaj  

Testing the Substrate-Envelope Hypothesis with Designed Pairs of Compounds [PDF]

, 2013
Acquired resistance to therapeutic agents is a significant barrier to the development of clinically effective treatments for diseases in which evolution occurs on clinical time scales, frequently arising from target mutations.
Ali, Akbar, Altman, Michael D., Cao, Hong, Nalam, Madhavi N. L., Rana, Tariq M., Schiffer, Celia A., Shen, Yang, Tidor, Bruce   +7 more
core   +1 more source

Darunavir pharmacokinetics with an increased dose during pregnancy.

Journal of Acquired Immune Deficiency Syndromes, 2020
BACKGROUND This study aims to evaluate the pharmacokinetics of an increased dose of darunavir (800 mg twice daily) with 100 mg ritonavir during pregnancy and postpartum.
A. Eke, A. Stek, Jiajia Wang, Régis Kreitchmann, D. Shapiro, E. Smith, N. Chakhtoura, E. Capparelli, M. Mirochnick, B. Best   +9 more
semanticscholar   +1 more source

Gatherings in Esophagology: Innovations and Future Directions in the Diagnosis and Management of Reflux Disease

Annals of the New York Academy of Sciences, Volume 1557, Issue 1, March 2026.
Bringing together experts in reflux diseases, including gastroenterologists, surgeons, endoscopists, laryngologists, pulmonologists, and research scientists, the inaugural Gatherings in Esophagology (GiE) was held May 30–31, 2025, in France as a new initiative of Organisation mondiale d'Etudes Spécialisées pour les maladies de l'Oesophage (OESO).
Jennifer Cable, Robert Giuli, Mark R. Fox, Rachel L. Rosen, Luis R. Valdovinos‐García, Stefano Siboni, John O. Clarke, Nikki Johnston, Tina L. Samuels, Carmelo Scarpignato, Ellen M. Stein, Ronnie Fass, José María Remes‐Troches, Abraham Khan, Afrin Kamal Rahman, Kristle Lynch, Daniela Jodorkovsky, Marcelo F. Vela, Alexandra Vandenberg, Braden Kuo, Pelin Ergun, Sigh Pichamol Jirapinyo, Emanuele Asti, Salvatore Tolone, Eric G. Sheu, Renato Salvador, Marco Sozzi, Inna A. Husain, Justin C. Wu, Anthony Hobson, Nirmal S. Sharma, Wai‐Kit Lo, Daniel R. Duncan, C. Prakash Gyawali, Walter Chan, Daniel Sifrim, Edoardo Savarino, Nicola de Bortoli, Benjamin D. Rogers   +38 more
wiley   +1 more source

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study

HIV Research & Clinical Practice, 2019
Background: The once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is approved for the treatment of HIV-1 infection.
Bruce Rashbaum, Christoph D. Spinner, Cheryl McDonald, Cristina Mussini, John Jezorwski, Donghan Luo, Erika Van Landuyt, Kimberley Brown, Eric Y. Wong   +8 more
doaj   +1 more source

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

BMC Infectious Diseases, 2019
Background Direct comparisons between lamivudine plus bPIs and lamivudine plus dolutegravir as maintenance strategies in virologically-suppressed HIV positive patients are lacking.
Alberto Borghetti, Francesca Lombardi, Roberta Gagliardini, Gianmaria Baldin, Arturo Ciccullo, Davide Moschese, Arianna Emiliozzi, Simone Belmonti, Silvia Lamonica, Francesca Montagnani, Elena Visconti, Andrea De Luca, Simona Di Giambenedetto   +12 more
doaj   +1 more source